Ensemble Discovery is developing a new class of therapeutics - the Ensemblins™, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. We have two complementary platforms that provide access to these molecules. Firstly, we use our proprietary DNA-Programmed Chemistry™ (DPC™) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, we have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Ensemble Discovery Corp.
99 Erie Street Cambridge, MA 02139 USA